1-2 of 2
Ashkan Emadi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine

Casey L. O'Connell, Maria R. Baer, Andreas Due Ørskov, Sunil Kumar Saini, Vu H. Duong, Patricia Kropf, Jakob Werner Hansen, Denice Tsao-Wei, Hyo Sik Jang, Ashkan Emadi, Staffan Holmberg-Thyden, Jack Cowland, Brett T. Brinker, Kristin Horwood, Ryan Burgos, Galen Hostetter, Benjamin A. Youngblood, Sine Reker Hadrup, Jean-Pierre Issa, Peter Jones, Stephen B. Baylin, Imran Siddiqi, Kirsten Grønbaek
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (24): 5306–5316.
https://doi.org/10.1158/1078-0432.CCR-22-1810
Published: 15 December 2022
View article titled, Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine
Open the PDF for Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine in another window
Includes: Supplementary data
Journal Articles

Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia

Maria R. Baer, Aksinija A. Kogan, Søren M. Bentzen, Tian Mi, Rena G. Lapidus, Vu H. Duong, Ashkan Emadi, Sandrine Niyongere, Casey L. O'Connell, Benjamin A. Youngblood, Stephen B. Baylin, Feyruz V. Rassool
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1313–1322.
https://doi.org/10.1158/1078-0432.CCR-21-3729
Published: 01 April 2022
View article titled, Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia
Open the PDF for Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia in another window
Includes: Supplementary data